

Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases

Konstantinos Papamichael, MD, PhD,* Gabriele Stocco, PharmD, PhD,†‡ and Ainhua Ruiz del Agua, PhD§

Background: Therapeutic drug monitoring (TDM) is a decision-making tool for optimizing the use of certain therapies. In this article, the authors review the role of proactive TDM of biological agents in patients with inflammatory bowel disease (IBD) and other immune-mediated inflammatory diseases (IMID). They also discuss the future of TDM as a component of personalized medicine from the clinical laboratory perspective.

Methods: This narrative review originated from proceedings of the fifth biannual *Challenges in Therapeutic Drug Monitoring* seminar and was supplemented by additional literature identified at various stages of critical review.

Results: Proactive TDM aims to achieve adequate concentrations of biological drugs, such that patients attain and maintain an optimal treatment response. Proactive TDM may also have a role in de-escalating anti-tumor necrosis factor therapy in patients in clinical remission and in optimizing infliximab monotherapy as an alternative to combination therapy with an immunomodulator. A major proactive TDM application is in pediatric patients with IBD. Achieving mucosal healing in children with IBD requires that infliximab or adalimumab concentrations are monitored early during induction therapy, with dose modifications guided by the timing (week) of measurement. Recent innovations in biological therapy include international standards for infliximab and adalimumab for the global harmonization of bioactivity and monostest devices with an accuracy equivalent to that of conventional enzyme-linked immunosorbent assays and quicker turnaround times.

Conclusions: Despite several knowledge gaps regarding proactive TDM of anti-tumor necrosis factor therapy in patients with IMID, growing evidence suggests that it is associated with better outcomes than empiric optimization and/or reactive TDM in IBD. Enhanced pharmacokinetic modeling to predict drug exposure and patient genotyping for the precise application of proactive TDM are considered key elements to optimize biological therapy in the future.

Key Words: therapeutic drug monitoring, biologicals, immune-mediated inflammatory diseases, pediatric inflammatory bowel disease, biobetters

(*Ther Drug Monit* 2023;45:579–590)

INTRODUCTION

Therapeutic drug monitoring (TDM) is a clinical decision-making tool that aims to optimize the use of biological therapies and provide personalized medicine to patients with inflammatory bowel disease (IBD) and other chronic immune-mediated inflammatory diseases (IMID). TDM of biological drugs is paramount given the high interindividual and intraindividual variability in serum concentrations at both the patient and population levels.¹

Reactive TDM is defined as the measurement of biological drug concentrations and antidrug antibody levels in the setting of primary nonresponse (lack of response since the start of therapy), secondary loss of response (disease flare after initial response), or an infusion reaction.² Proactive TDM is defined as the scheduled measurement of drug

Received for publication November 17, 2022; accepted February 23, 2023.

From the *Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA; †Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; ‡Institute for Maternal and Child Health, IRCCS “Burlo Garofolo,” Trieste, Italy; and §Progenika Biopharma Grifols, Derio, Vizcaya, Spain

Conflicts of Interest: Konstantinos Papamichael has received lecturer/speaker fees from Grifols and Physicians Education Resource LLC, scientific advisory board fees from ProciseDx Inc and Scipher Medicine Corporation, and is a consultant for Prometheus Laboratories Inc. Gabriele Stocco has received lecturer fees from Grifols. Ainhua Ruiz del Agua is a full-time employee of Progenika Biopharma Grifols.

Author contributions: Conceptualization, K.P., G.S., and A.R.A.; methodology, K.P., G.S., and A.R.A.; software, K.P., G.S., and A.R.A.; validation, K.P., G.S., and A.R.A.; formal analysis, K.P., G.S., and A.R.A.; investigation, K.P., G.S., and A.R.A.; resources, K.P., G.S., and A.R.A.; data curation, K.P., G.S., and A.R.A.; writing—original draft preparation, K.P., G.S., and A.R.A.; writing—review and editing, K.P., G.S., and A.R.A.; visualization, K.P., G.S., and A.R.A.; supervision, K.P., G.S., and A.R.A.; project administration, K.P., G.S., and A.R.A.; and funding acquisition, K.P. and G.S. All authors have read and agreed to the published version of the manuscript.

Correspondence: Konstantinos Papamichael, Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215 (e-mail: kpapamic@bidmc.harvard.edu).

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

concentrations and antidrug antibody levels to achieve an adequate concentration threshold such that patients attain and maintain an optimal response to the biological treatment.²

Although reactive TDM has become the standard of care for optimizing biological therapies in IBD, recent data demonstrate the benefits and important role of proactive TDM in patient management.³ Maintaining the concentration of biological agents within a therapeutic window according to the timing of measurement aims to prevent relapse and reduce the risk of complications.⁴

This narrative review originated from proceedings of the fifth biannual *Challenges in Therapeutic Drug Monitoring* seminar in which recent evidence regarding the role of proactive TDM of biological agents in patients with Crohn's disease (CD), ulcerative colitis (UC), and other IMID was presented and interpreted. Special focus was placed on the application of proactive TDM in pediatric IBD. Also explored was the future of TDM as a major component of personalized medicine from the perspective of the clinical laboratory. Throughout the development of this manuscript, the source material selected by the authors was supplemented with additional literature known to the authors or identified by critical reviewers.

NEW INSIGHTS FOR PROACTIVE TDM OF BIOLOGICALS

Proactive TDM for Optimizing Biologicals in IBD and Other IMID

Numerous exposure–outcome relationship studies have shown that higher concentrations of anti–tumor necrosis factor (anti-TNF) biological agents are associated with higher rates of favorable therapeutic outcomes in IBD⁵ and other IMID,⁶ most of which refer to infliximab and adalimumab. In parallel, there is cumulative evidence to indicate that proactive TDM of anti-TNF therapy is associated with better outcomes than reactive TDM or empirical dose optimization in patients with IBD.^{7–23} A recent systematic review and meta-analysis showed that proactive TDM of anti-TNF therapy compared with standard of care was associated with reduced treatment failure and surgical rates as well as improved endoscopic remission and response.⁹ The same meta-analysis demonstrated that proactive compared with reactive TDM of anti-TNF therapy was related to less hospitalization and treatment failure.⁹

Currently, there are 6 published randomized controlled trials (RCTs) of proactive TDM of infliximab^{17–19} or adalimumab^{20–22} in IBD, although the SERENE (Study of a Novel Approach to Induction and Maintenance Dosing with Adalimumab) trials in CD²¹ and UC²² were not powered to confirm the role of proactive TDM of adalimumab in IBD. Two of the RCTs met their primary outcome.^{19,20} Pharmacokinetic (PK)-driven dashboard dosing of infliximab was associated with a higher proportion of patients with IBD in sustained clinical remission after 1 year compared with standard dosing.¹⁹ Proactive TDM of adalimumab was associated with a higher proportion of pediatric patients with IBD with sustained corticosteroid-free clinical remission rate at all visits (week 8 through week 72) compared with


reactive TDM.²⁰ A major limitation of all 6 RCTs was the relatively low targeted trough concentrations of anti-TNF therapy (3 µg/mL for infliximab; 5 µg/mL for adalimumab).⁵ Notwithstanding, in 3 of the studies, proactive TDM provided a significant benefit over standard dosing for secondary outcomes including stringent composite end points.^{17,19,20}

The Norwegian Drug Monitoring (NOR-DRUM) RCT enrolled patients with a range of IMIDs (CD, UC, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis) who were starting treatment (part A) or receiving maintenance therapy (part B) with infliximab.²³ In both parts A and B, patients were randomized 1:1 to receive either proactive TDM with dose and interval adjustments based on scheduled monitoring of serum drug levels and antidrug antibodies (TDM group) or standard infliximab therapy without drug and antibody level monitoring (standard therapy group). In part A (infliximab induction therapy), no statistically significant difference in 30-week remission rates was observed between proactive TDM and standard therapy, possibly (as suggested by the investigators) because the benefits of TDM were diminished by high drug exposure during induction therapy.²⁴ Nonetheless, it is suggested that patients at high risk of developing antidrug antibodies may benefit from proactive TDM during induction therapy.²⁵ Timing may also have influenced the results; because infliximab dose adjustments were not permitted before week 14 of induction therapy, there was limited time (16 weeks) in which to detect a difference in remission rates between proactive TDM and standard therapy.²⁶ In part B of the NOR-DRUM study (infliximab maintenance therapy), patients receiving proactive TDM had a lower probability of disease worsening at 52 weeks compared with the standard therapy group (hazard ratio [HR] 2.1; 95% confidence interval [CI] 1.5–2.9; Fig. 1).²⁷

Several medical societies and TDM expert groups recommend proactive TDM of anti-TNF therapy in IBD,^{28–33} although the American Gastroenterology Association and the European Crohn's and Colitis Organisation regard existing RCT evidence as insufficient to support the routine use of proactive TDM in clinical practice (Table 1).^{34,35} Two RCTs of proactive TDM are currently in progress. The OPTIMIZE (Proactive infliximab optimization using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease) study is comparing proactive TDM combined PK dashboard-driven infliximab dosing with standard-of-care dosing in patients with CD.^{36,37} The PROACTIVE (Prospective randomized controlled trial of adults with perianal fistulizing Crohn's disease and optimized therapeutic infliximab levels) study is investigating whether optimizing infliximab dosing to higher trough levels using proactive TDM will improve outcomes compared with standard therapy in patients with perianal fistulizing CD.³⁸ In both RCTs, proactive TDM is initiated early during induction therapy.

Proactive TDM algorithms are available to guide management strategies for patients with IBD during infliximab maintenance therapy. According to a suggested algorithm adapted from Papamichael and Cheifetz,³⁹ patients with supratherapeutic infliximab concentrations (>10–15 µg/mL)

FIGURE 1. Time to disease worsening in the standard therapy group and therapeutic drug monitoring group of the NOR-DRUM B study. Reproduced with permission from Syversen et al.²⁷



are candidates for treatment de-escalation. Patients with therapeutic infliximab concentrations (5–10 $\mu\text{g/mL}$) can continue with the same regimen. Patients with undetectable or low infliximab concentrations ($<5 \mu\text{g/mL}$) are further categorized according to their antibodies to infliximab (ATI) level. Those with an undetectable or low ATI titer ($<8 \mu\text{g/mL}$ evaluated by enzyme-linked immunosorbent assay [ELISA] or $<10 \text{ U/mL}$ evaluated by homogeneous mobility shift assay) should undergo infliximab optimization by adding an immunomodulator (IMM) or by shortening the dosing interval and/or increasing the dose. Those with a high ATI titer should discontinue infliximab and switch within the drug class using either combination therapy with an IMM or monotherapy with proactive TDM or, alternatively, change outside the drug class. This latter approach is supported by recent evidence suggesting that patients with immunogenicity to previous anti-TNF therapy are more prone to developing anti-drug antibodies against a subsequent anti-TNF agent.^{40,41}

Proactive TDM During and Early After Induction Therapy in IBD

Higher concentrations of biological agents during and early after induction therapy have been shown to be associated with higher rates of favorable therapeutic outcomes in IBD.⁴² In addition to improving clinical outcomes and patients' quality of life, proactive TDM during induction therapy may provide a range of pharmacoeconomic and PK benefits (Fig. 2).⁴² The utility of early proactive TDM application was shown in a real-world prospective study in which a PK dashboard model was used to guide infliximab dosing during induction therapy in patients with IBD.⁴³ Adaptive Bayesian dashboard systems incorporate the previously measured drug concentration and several patient-related factors (eg, body weight, C-reactive protein, and albumin) to inform a subsequent dose.⁴⁴ Applying this model, the need for accelerated infliximab dosing at the third infusion to achieve a predefined therapeutic threshold (10 $\mu\text{g/mL}$) at the fourth infusion was forecast in 80% of patients who

began treatment at a 5-mg/kg dose and in about 60% of those who began treatment at a 10-mg/kg dose.⁴³ Adherence to dashboard-driven forecasts for the third, and especially the fourth, infliximab infusion was associated with greater treatment durability and less immunogenicity.⁴³ Several studies have assessed PK modeling for anti-TNF agents to treat patients with IBD.⁴⁵

Potential Applications of Proactive TDM

The key applications of proactive TDM of anti-TNF therapy in IBD include guiding treatment de-escalation and optimizing infliximab monotherapy.³⁹

De-Escalation of ANTI-TNF Therapy

Preliminary data suggest that proactive TDM can efficiently guide anti-TNF therapy de-escalation in patients with IBD. French investigators showed that TDM-based de-escalation in patients with clinical remission and infliximab trough concentrations above 7 $\mu\text{g/mL}$ significantly improved the cumulative probability of being relapse-free compared with de-escalation based on clinical remission alone (HR 0.45; $P = 0.024$).⁴⁶ The probability of sustained remission was found to be greater in patients with infliximab trough concentrations $\geq 2.4 \mu\text{g/mL}$ (versus $<2.4 \mu\text{g/mL}$) at the time of de-escalation.⁴⁷ The feasibility of de-escalating anti-TNF therapy based on proactive TDM has been demonstrated in several other studies, including RCTs,^{8,17,19,20} with de-escalation rates of 13%–50% suggesting potential for lowering treatment costs. Proactive TDM can also guide the withdrawal of an IMM in patients with IBD in remission receiving anti-TNF combination therapy.^{48,49}

Optimized Infliximab Monotherapy


Retrospective studies have suggested that optimized infliximab monotherapy using proactive TDM-guided dose escalations is as effective as combination therapy as regards clinical outcomes⁵⁰ and treatment durability in adult and pediatric patients with IBD.^{50,51} This is relevant clinically because

TABLE 1. Recommendations of Medical Societies and Expert Groups Regarding Proactive TDM of Biological Therapy in IBD

Medical Society or Expert Group	Methodology	Year [Reference]	Recommendations
Australian IBD Group	Modified Delphi	2017 [Mitrev 2017] ²⁸	• In patients in clinical remission after anti-TNF therapy induction, TDM should be considered to guide management. • TDM should be considered periodically in patients in clinical remission if the results are likely to impact management.
American Gastroenterological Association	GRADE	2017 [Feuerstein 2017] ³⁴	• In adult patients with quiescent IBD treated with anti-TNF agents, no recommendation is made regarding the use of routine proactive TDM (knowledge gap).
British Society of Gastroenterology	GRADE	2019 [Lamb 2019] ²⁹	• All patients with IBD should be reviewed 2–4 weeks after completing loading doses of anti-TNF therapy to assess response and optimize maintenance dosing based on clinical response and measures such as serum drug and antidrug antibody concentrations, blood inflammatory markers, fecal biomarkers, or endoscopy (good practice recommendation).
Building Research in IBD Globally (BRIDGE) Group	Modified Delphi	2019 [Papamichael 2019] ³⁰	• It is appropriate to order drug/antibody concentration testing at least once during maintenance for patients on all anti-TNFs. • It is appropriate to order drug/antibody concentration testing in responders at the end of induction for all anti-TNFs.
European Crohn's and Colitis Organisation	GRADE	2020 [Torres 2020] ³⁵	• In patients with CD in clinical remission under anti-TNF treatment, there is currently insufficient evidence to recommend for or against the use of proactive TDM to improve clinical outcomes as compared with routine care (weak recommendation, moderate quality evidence).
European Crohn's and Colitis Organisation–European Society of Pediatric Gastroenterology, Hepatology, and Nutrition	GRADE	2021 [Van Rheenen 2021] ³¹	• In patients on anti-TNF agents, early proactive TDM followed by dose optimization is recommended (level of evidence: 2; agreement: 87.5%).
IBD TDM Expert Group	Modified Delphi	2021 [Cheifetz 2021] ³²	• Proactive TDM should be performed after induction for patients treated with anti-TNF therapy (agreement: 90%; strength of recommendation: 9). • Proactive TDM should be performed at least once during maintenance therapy for patients treated with anti-TNF therapy (agreement: 90%; strength of recommendation: 8.8). • Proactive TDM should be used after reactive TDM of anti-TNF therapy (agreement: 80%; strength of recommendation: 8.1). • More data are needed to support the use of proactive TDM for biologics other than anti-TNF therapies (agreement: 100%; strength of recommendation: 9.2).
Emirates Society of Gastroenterology and Hepatology	Delphi	2021 [Annese 2021] ³³	• TDM should be recommended at the end of induction in responders to predict final outcome (agreement: 100%). • TDM should be performed at least once in responders during maintenance therapy or when the results will alter treatment decisions (agreement: 100%). • Proactive TDM is desirable during maintenance phase to predict loss of response (agreement: 90%).

CD, Crohn's disease; IBD, inflammatory bowel disease; TDM, therapeutic drug monitoring; TNF, tumor necrosis factor.

FIGURE 2. Potential benefits of proactive therapeutic drug monitoring (TDM) of anti-tumor necrosis factor (TNF) agents during induction therapy. Reproduced with permission from Sparrow et al.⁴² IMM = immunomodulators; PNR = primary non-response; QOL = quality of life; SLOR = secondary loss of response.



combination therapy may be associated with an increased risk of infection and malignancy.⁵²

A post hoc analysis of the Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC) showed that mucosal healing rates at week 26 were comparable between patients receiving infliximab monotherapy or combination therapy (infliximab + azathioprine) within quartiles of infliximab serum concentrations,⁵³ although this finding must be confirmed in prospective RCTs. The concept of optimized infliximab monotherapy as an alternative to combination therapy was further supported by a large retrospective study showing that thiopurines have a limited impact on ATI formation in the presence of elevated infliximab concentrations (>5 µg/mL).⁵⁴

Recently, it was reported that optimized infliximab monotherapy based on proactive TDM prevented ATI formation and drug discontinuation in patients with IBD regardless of their HLA-DQA1*05 allele carrier status.⁵⁵ Again, this is clinically relevant because HLA-DQA1*05 carriage has been associated with lower maintenance-phase infliximab concentrations,⁵⁶ as well as the development of ATI and antibodies to adalimumab,^{57,58} in patients with IBD.

Cost-Effectiveness of Proactive TDM

Until recently, data on the cost-effectiveness of proactive TDM in IBD were limited and largely inferred based on the putative benefits associated with superior disease control. A Spanish group undertook a systematic review of cost-effectiveness analyses of studies that applied TDM of anti-TNFs in IBD.⁵⁹ Of 13 studies identified for inclusion (12 of infliximab), 4 modeling studies,^{60–63} 1 prospective observational study,⁶⁴ 1 retrospective observational study,⁶⁵ 1 non-randomized clinical trial,⁶⁶ and 1 RCT¹⁷ reported economic outcomes for proactive TDM. Overall, the incremental cost-effectiveness ratio for proactive TDM versus an empirical strategy ranged from €57,000 to €3.9 million, indicating cost-effectiveness. However, the analysis was limited by the considerable clinical and methodological heterogeneity among the studies.⁵⁹

Knowledge Gaps Regarding the Utilization of Proactive TDM of Biologics

Despite growing evidence supporting proactive TDM of biologics in IMID, several knowledge gaps remain.

Optimal target concentrations of biologics have yet to be established as these may depend on several aspects of treatment: timing of measurement (induction/maintenance); route of drug administration^{67,68}; desired therapeutic outcome^{30,69}; type of assay^{70,71}; and patient phenotype.⁷² Numerous data from prospective studies and post hoc analyses of RCTs suggest a link between higher biological drug concentrations and the achievement of increasingly stringent therapeutic outcomes.^{5,30,32} Cheifetz et al³² have suggested therapeutic windows for biologics during maintenance therapy of 5–10 µg/mL for infliximab, 8–12 µg/mL for adalimumab, 13–15 µg/mL for certolizumab pegol, 1–3 µg/mL for golimumab, 10–15 µg/mL for vedolizumab, and 1–3 µg/mL for ustekinumab. Although useful as a general guide, until confirmed in prospective RCTs, these concentration ranges should be regarded solely as reference points. As practice varies, it may be necessary for IBD centers to establish their own optimal therapeutic ranges for biologics based on individual circumstances (eg, cohort population and type of assay).

The role of proactive TDM in guiding treatment with non-anti-TNF biologics should be better defined. Although higher vedolizumab and ustekinumab concentrations have been associated with higher rates of favorable therapeutic outcomes in IBD,⁵ direct comparisons between proactive and reactive TDM, or between proactive TDM and standard of therapy for non-anti-TNF biologics, are lacking.

Another uncertainty relates to the role of intermediate (between trough) and peak drug concentrations in proactive TDM. Higher infliximab concentrations early in treatment (at 4, 8, and 10 weeks) were associated with higher rates of favorable therapeutic outcomes, including endoscopic remission and drug retention in IBD.⁷³ An exposure-response relationship was recently reported between higher peak ustekinumab concentrations measured during the first 2 weeks of treatment and the achievement of robust end points including

endoscopic remission at 6 months in patients with CD.⁷⁴ However, data are limited, and the concentration thresholds reported in these studies must be verified in prospective RCTs.

By avoiding the time lag associated with conventional clinical laboratory processing of serum samples, point-of-care testing can facilitate prompt ad hoc dose adjustment. However, a recent pragmatic study that compared “ultra-proactive” TDM (center A) with reactive TDM (center B) in patients with IBD receiving maintenance therapy found no differences between cohorts in infliximab failure rates (19% versus 10%; $P = 0.08$) or clinical remission rates (75% versus 83%; $P = 0.17$) after 1 year of follow-up.⁷⁵ The apparent lack of benefit of ultra-proactive TDM might be explained by certain methodological features of the study. The outcomes were compared between cohorts from 2 different hospitals, introducing a potential bias. Target infliximab trough serum concentrations of 3–7 $\mu\text{g/mL}$ during the optimization and maintenance phases may have been insufficient in some patients. In addition, the 1-year follow-up period may have been insufficient to detect statistical differences between the treatment arms. The potential benefits of ultra-proactive TDM merit further study in well-designed comparative RCTs.

TDM OF BIOLOGICAL THERAPY IN PEDIATRIC PATIENTS WITH IBD

An important application of proactive TDM is childhood-onset IBD, which, relative to later-onset IBD, is characterized by more extensive intestinal involvement and rapid clinical progression.^{76,77} Early and effective therapy is critical to avoid compromising a child's development, growth, and maturation. Many children with IBD require aggressive anti-TNF therapy on diagnosis.

Proactive TDM in Pediatric IBD

There are several compelling reasons for using proactive TDM in pediatric patients with IBD. Administering an anti-TNF agent at doses insufficient to maintain a minimum therapeutic concentration throughout the dosing interval can result in many days of nonoptimal exposure, increasing the risk of antidrug antibody formation and the consequent loss of response. This is particularly relevant with infliximab maintenance therapy because of the 2-monthly dosing interval.⁷⁸ The high interindividual variability in anti-TNF concentrations observed in children is likely due to factors influencing drug clearance, such as demographics, disease variables, and immunogenicity.⁷⁹ Young children (<10 years) in particular tend to have rapid infliximab clearance and require intensified treatment regimens to achieve therapeutic concentrations.⁸⁰ Although overexposure to anti-TNF agents is not a safety concern, it can waste resources. Proactive TDM can rationalize the use of anti-TNF agents in pediatric IBD and permit treatment de-escalation in suitable patients.^{81,82}

In the pediatric Crohn's disease adalimumab level-based optimization treatment (PAILOT) RCT, proactive versus reactive TDM of adalimumab was associated with a significantly higher rate of corticosteroid-free clinical remission (82% versus 48%; $P = 0.002$).²⁰ Elsewhere, proactive TDM was associated with a significant reduction in the

number of children requiring a switch of their primary biological and with superior clinical outcomes including a higher rate of steroid-free clinical remission at 1.5-year follow-up and fewer IBD-related surgeries.¹⁶ The correlation between anti-TNF drug concentrations and therapeutic response in patients with IBD supports the use of proactive TDM for prognostic purposes. In children with IBD, infliximab trough concentrations at week 14 (fourth infusion) were associated with persistent remission status at week 54.⁸³ Another group showed that infliximab concentrations at week 14 in pediatric patients with IBD predicted efficacy at 1 year, with an association evident as early as 6 weeks (third infusion) of induction therapy.⁸⁴ Adalimumab concentrations measured at the end of induction therapy (4 weeks) and during routine clinic visits, not necessarily at the trough level, have also been shown to correlate with long-term response in children with IBD.⁸⁵

To achieve mucosal healing in pediatric luminal CD, the European Crohn's and Colitis Organisation–European Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ECCO-ESPGHAN) guidelines recommend that infliximab concentrations be measured before the fourth infusion (14 weeks) and that dose modifications be considered if the concentration is below 5 $\mu\text{g/mL}$. At-risk patients should have their infliximab concentrations measured at the second or third infusion to target a trough concentration of $\geq 25 \mu\text{g/mL}$ at week 2 and $\geq 15 \mu\text{g/mL}$ at week 6. Adalimumab concentrations should be measured at weeks 4 and 8 of therapy aiming for a concentration above $\geq 7.5 \mu\text{g/mL}$ (Fig. 3).³¹

TDM Algorithm for Pediatric Patients With Active CD

The ECCO-ESPGHAN consensus paper on personalized therapy includes a TDM algorithm for pediatric patients with active CD despite anti-TNF therapy.³¹ According to this treatment plan, if the anti-TNF concentration is in range and the patient is not responding (pharmacodynamic failure), the patient should be switched to an out-of-class biological. If the anti-TNF concentration is low, the recommendation is to check for antidrug antibodies and, if present, measure the titer. High-titer antidrug antibodies indicate the need to switch drug, for example, from infliximab to adalimumab. In the case of low-titer antidrug antibodies, options are to escalate the dose of anti-TNF and/or add an IMM. In the absence of antidrug antibodies (PK failure), drug escalation is recommended. Despite the relatively straightforward nature of these therapeutic pathways, there is a lack of agreement regarding what constitutes a low or high titer of antidrug antibodies, and no World Health Organization (WHO) international standards are available to quantify antidrug antibodies.

Measuring Anti-TNF Drug Concentrations and Antidrug Antibodies in Pediatric IBD

Several assays are available to measure anti-TNF concentrations and antidrug antibodies in pediatric IBD (Fig. 4).⁸⁶ The most common is the ELISA, although it is best suited for high-throughput settings owing to its multiwell plates. Lateral flow is a point-of-care assay for single-patient analysis that has shown good agreement with traditional




FIGURE 3. Target trough levels of infliximab and adalimumab to achieve mucosal healing in pediatric luminal Crohn's disease. Reproduced with permission from van Rheenen et al.³¹

ELISAs for the quantification of infliximab.⁸⁷ Other assays are comparatively labor-intensive and require dedicated instrumentation, which may be difficult for most laboratories to implement. Recently, atomic force microscopy-based nanoassays have been proposed to measure drug concentrations in the serum samples of patients treated with anti-TNF agents. This assay evaluates the variation in the height signal of a nanostructured gold surface covered with a self-assembled monolayer of alkanethiols. DNA conjugated with TNF, which can bind to anti-TNF agents, is embedded inside this monolayer. In a proof-of-concept study, a significant association between height variation and anti-TNF concentration was reported.⁸⁸ A potential application of this technique would be to also embed various proteins in the testing surface (eg, infliximab

or a portion of the drug) to enable the detection of antidrug antibodies in a single run for a specific sample.

Genetic Variation May Influence Response to Anti-TNF Therapy in Pediatric IBD

The high interpatient variability in response to anti-TNF therapy may have a genetic component. Several studies have investigated gene variants encoding proteins involved in immune processes, inflammation, autophagy, and apoptosis.⁸⁹ Confirming an association between genetic variants and treatment response as well as drug PK properties would provide useful markers for genotyping before the start of anti-TNF therapy and enable the identification of patients more likely to respond to treatment.⁴⁵




FIGURE 4. Schematic representation of methods used for therapeutic drug monitoring. Reproduced with permission from Franca et al.⁸⁶ ELISA = enzyme-linked immunosorbent assay; LF = lateral flow; RGA = reporter gene assay; SPR = surface plasmon resonance; HMSA = homogenous mobility shift assay; RIA = radioimmunoassay; TDM = therapeutic drug monitoring.

A genetic variant of particular interest is the coding nonsynonymous variant rs396991, commonly referred to by its protein alleles Phe158Val,⁹⁰ in the *FCGR3A* gene. The *FCGR3A* gene encodes a receptor for the Fc portion of immunoglobulin G and is involved in the removal of antigen-antibody complexes from the circulation, as well as other effects including antibody-dependent cellular-mediated cytotoxicity.⁹¹ In an Italian cohort of 76 pediatric patients with IBD, those with variant *FCGR3A* showed inferior clinical responses at the end of induction, at 22 weeks, and at 52 weeks of infliximab therapy. A significant association between variant *FCGR3A* and lower median infliximab concentrations during maintenance therapy was also observed. Furthermore, patients with the variant allele had a higher production rate of antidrug antibodies.⁹²

THE FUTURE OF TDM INVOLVES CONSTANTLY ADAPTING TO IMPROVEMENTS IN BIOLOGICALS

Monoclonal antibodies (mAbs) have advanced considerably since they were first used to treat patients with IBD and other IMID. The evolution from murine to human sequences has lowered their immunogenicity and improved their efficacy and efficiency. Subcutaneous formulations permit at-home use, substantially reducing drug delivery costs and health resource utilization compared with intravenous formulations.⁹³ Biosimilars have brought further cost savings to health systems and broadened patient access to treatment. The most recent innovation, biobetters, offers improved adaptations of the originator biological, that is, biosimilars with

value-added features, such as subcutaneous administration and/or high-concentration citrate-free formulations.

Interchangeability Between Reference Biologicals and Their Biosimilars

The concept of biosimilars refers to the exchange of one medicine with another that is expected to have the same clinical effect. In the case of biologicals, this involves replacing a reference drug with a biosimilar (and vice versa) or a biosimilar with another biosimilar. Initial concerns about interchangeability were resolved by studies showing no differences in clinical outcomes between patients maintained on a reference biological (infliximab or adalimumab) and those transitioned to the respective biosimilars.^{94–98} A recent large systematic review (178 studies, >21,000 switched patients) concluded that switching between reference products and biosimilars was not associated with any major efficacy, safety, or immunogenicity issues.⁹⁹

To examine interchangeability at the laboratory level, a study investigated the potential for ATI to cross-react with reference infliximab and 2 approved biosimilars (CT-P13 and SB2).¹⁰⁰ Patients with IBD from the BIOSIM-01 study who had tested positive for ATI during routine analysis of trough sera were consecutively included in the study (23 patients/76 sera samples). Separate bridging ELISAs were constructed using the 3 drugs. ATI titers were compared in patients who had been treated with reference infliximab only or CT-P13 only and in infliximab/CT-P13 switchers. Antibodies raised against reference infliximab cross-reacted fully (100% agreement) with those formed against CT-P13 and SB2. Antibodies raised against CT-P13 cross-reacted fully (100% agreement) in

ELISAs for reference infliximab and SB2. Based on their findings, the authors concluded that “CT-P13 and SB2 are interchangeable and that switching between biosimilars and reference drug will not lead to differences in ATI production.”

TRENDS IN TDM FOR CLINICAL LABORATORIES

Clinical laboratories that provide TDM services have a responsibility to keep apprised of developments in biological agents. An example is subcutaneous formulations which, owing to PK differences, produce serum concentrations many-fold higher than those of intravenous formulations from the start of induction therapy.^{67,68,101,102} As such, TDM assays must be able to measure a range of drug concentrations sufficiently broad to cover those reported in clinical studies of intravenous and subcutaneous formulations of biologics.

Clinical laboratories are constantly striving to increase their efficiency and reduce costs. ELISAs are often regarded as the gold standard in assays, but their utility in proactive TDM is hampered by long turnaround times between sampling and results. Point-of-care assays provide results equivalent to those obtained with conventional ELISAs, but within a 30-minute timeframe. Another alternative to ELISAs is a monotest multiparametric immunoassay, which has shown high within-run (repeatability) and within-device (reproducibility) precision in validation testing. Method comparison studies with human clinical samples showed 100% positive and negative agreement and 100% concordance, with a strong Pearson correlation between the Chorus Promonitor (Progenika Biopharma, S.A. Grifols), the monotest multiparametric product, and the Promonitor ELISA (Progenika Biopharma, S.A. Grifols). Evaluation of additional performance parameters showed no statistical differences between the monotest multiparametric immunoassay and ELISA.

Harmonization of TDM Assays

The World Health Organization has developed international reference standards for mAbs in response to the increasing number of biosimilars available or in development. By providing a global benchmark of biological activity, international standards support bioassay performance, calibration, and validation and facilitate the comparability of bioassay data across multiple stakeholders.^{103,104} International standards are available commercially for infliximab (NIBSC code 16/170) and adalimumab (NIBSC code 17/236).^{103,104} TDM assays for infliximab or adalimumab must be validated against these international standards. Promonitor ELISA assays were used in a collaborative study involving hospitals and clinical laboratories to assess the suitability of the WHO international standards. The accuracy or closeness of agreement between the results provided by Promonitor ELISA and the true value of the analyte was assessed by measuring WHO international standards.

DISCUSSION, GAP ANALYSIS, AND OUTLOOK

Growing evidence suggests that proactive TDM of anti-TNF therapy in patients with IBD and other IMID is associated with better outcomes than empiric optimization and/or reactive

TDM. Key applications of proactive TDM in IBD may include de-escalation of anti-TNF therapy in patients in clinical remission and optimizing infliximab monotherapy as an alternative to combination therapy with an IMM. Recently, it was shown that early application of proactive TDM during infliximab induction therapy can facilitate earlier dose optimization, with an associated positive impact on treatment durability and the risk of immunogenicity.

Proactive TDM may be particularly important for achieving better outcomes in pediatric patients with IBD because this population is characterized by high infliximab clearance. Planned studies of proactive TDM in pediatric IBD include a RCT aimed at evaluating the effect of modifying infliximab induction therapy according to drug concentrations at week 6 (before the third infusion). Another planned RCT aims to assess the need for different protocols of personalized therapy in early onset IBD (children under 6 years of age) because these patients are less responsive and have higher rates of azathioprine and infliximab failure and adverse events than older children.^{105–107}

Short- to medium-term goals include establishing target drug concentration thresholds for biological agents, defining the role of proactive TDM for non-anti-TNF biologics, and incorporating PK dashboards to guide dosing decisions. The future of personalized medicine also includes the application of pharmacogenetics/pharmacogenomics (eg, Fc receptor proteins and human leukocyte antigen [HLA] alleles). Genotyping patients before the start of biological therapy and stratifying them according to the probability of nonresponse and inadequate drug exposure may allow for a more precise application of proactive TDM. In addition, refinements to PK modeling and dashboards that consider multiple covariates to predict drug exposure will be key to optimizing treatment with biologics for IBD and other IMID.

The success of TDM in the future requires adapting to changes and improvements in biological drugs and their biosimilars. Clinical laboratories must ensure that TDM assays cover a broad range of drug concentrations reported for intravenous and subcutaneous biological formulations. TDM assays must be validated against international standards to ensure their reliability and comparability of results with other commercially available assays. To this end, TDM assays should be interchangeable to provide clinical laboratories with more room to maneuver.

ACKNOWLEDGMENTS

Writing assistance for this article was provided by Kerry Dechant, ISMPP CMPP, on behalf of Content Ed Net (Madrid, Spain) with funding from Grifols S.A. (Barcelona, Spain).

REFERENCES

1. Gaspar VP, Ibrahim S, Zahedi RP, Borchers CH. Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine. *J Mass Spectrom.* 2021;56:e4788.
2. Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? *Nat Rev Gastroenterol Hepatol.* 2020;17:702–710.

3. Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? *Curr Opin Gastroenterol*. 2019;35:302–310.
4. Ben-Horin S. Drug level-based anti-tumor necrosis factor therapy: ready for prime time? *Gastroenterology*. 2015;148:1268–1271.
5. Papamichael K, Afif W, Drobne D, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. *Lancet Gastroenterol Hepatol*. 2022;7:171–185.
6. Papamichael K, Vogelzang EH, Lambert J, et al. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. *Expert Rev Clin Immunol*. 2019;15:837–848.
7. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. *Inflamm Bowel Dis*. 2014;20:1996–2003.
8. Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. *Clin Gastroenterol Hepatol*. 2017;15:1580–1588.e3.
9. Sethi S, Dias S, Kumar A, et al. Meta-analysis: the efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease. *Aliment Pharmacol Ther*. 2022. Online ahead of print. doi: 10.1111/apt.17313
10. Papamichael K, Juncadella A, Wong D, et al. Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease. *J Crohns Colitis*. 2019;13:976–981.
11. Fernandes SR, Bernardo S, Simões C, et al. Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease. *Inflamm Bowel Dis*. 2020;26:263–270.
12. Sánchez-Hernández JG, Rebollo N, Martín-Suarez A, et al. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease. *Br J Clin Pharmacol*. 2020;86:1165–1175.
13. Syed N, Tolaymat M, Brown SA, et al. Proactive drug monitoring is associated with higher persistence to infliximab and adalimumab treatment and lower healthcare utilization compared with reactive and clinical monitoring. *Crohns Colitis*. 2020;2:otaa050.
14. Lyles JL, Mulgund AA, Bauman LE, et al. Effect of a practice-wide anti-TNF proactive therapeutic drug monitoring program on outcomes in pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2021;27:482–492.
15. Fernandes SR, Serrazina J, Rodrigues IC, et al. Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease. *Eur J Gastroenterol Hepatol*. 2021;33:1539–1546.
16. Gasparetto M, Burgess N, Naik S, et al. Advantages of proactive therapeutic drug monitoring in a prospective cohort of children with inflammatory bowel disease treated with anti-TNF. *J Pediatr Gastroenterol Nutr*. 2022;74:484–489.
17. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. *Gastroenterology*. 2015;148:1320–1329.e3.
18. D'Haens G, Vermeire S, Lambrecht G, et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn's disease. *Gastroenterology*. 2018;154:1343–1351.e1.
19. Strik AS, Löwenberg M, Mould DR, et al. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients: a randomized controlled trial. *Scand J Gastroenterol*. 2021;56:145–154.
20. Assa A, Matar M, Turner D, et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn's disease compared with reactive monitoring. *Gastroenterology*. 2019;157:985–996.e2.
21. D'Haens GR, Sandborn WJ, Loftus EV, Jr, et al. Higher vs standard adalimumab induction dosing regimens and two maintenance strategies: randomized SERENE CD trial results. *Gastroenterology*. 2022;162:1876–1890.
22. Panés J, Colombel J-F, D'Haens GR, et al. Higher vs standard adalimumab induction and maintenance dosing regimens for treatment of ulcerative colitis: SERENE UC trial results. *Gastroenterology*. 2022;162:1891–1910.
23. Syversen SW, Goll GL, Jørgensen KK, et al. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). *Trials*. 2020;21:13.
24. Syversen SW, Goll GL, Jørgensen KK, et al. Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial. *JAMA*. 2021;325:1744–1754.
25. Curtis JR, Ogdie A, George MD. Treatment strategies for patients with immune-mediated inflammatory diseases. *JAMA*. 2021;325:1726–1728.
26. Wallace ZS, Sparks JA. Therapeutic drug monitoring for immune-mediated inflammatory diseases. *JAMA*. 2021;326:2370–2372.
27. Syversen SW, Jørgensen KK, Goll GL, et al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. *JAMA*. 2021;326:2375–2384.
28. Mitrev N, Vande Casteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. *Aliment Pharmacol Ther*. 2017;46:1037–1053.
29. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut*. 2019;68(suppl 3):s1–s106. Erratum in: *Gut*. 2021;70:1.
30. Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol*. 2019;17:1655–1668.e3.
31. van Rheenen PF, Aloï M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. *J Crohns Colitis*. 2020. jjaal161. Epub ahead of print.
32. Cheifetz AS, Abreu MT, Afif W, et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. *Am J Gastroenterol*. 2021;116:2014–2025.
33. Annese V, Nathwani R, Alkhatry M, et al. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. *Therap Adv Gastroenterol*. 2021;14:17562848211065329.
34. Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. *Gastroenterology*. 2017;153:827–834.
35. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. *J Crohns Colitis*. 2020;14:4–22.
36. Papamichael K, Jairath V, Zou G, et al. Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). *BMJ Open*. 2022;12:e057656.
37. ClinicalTrials.gov. *Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard versus Standard of Care in Patients with Crohn's Disease: The OPTIMIZE Trial*. Available at: <https://clinicaltrials.gov/ct2/show/NCT04835506> (First Posted: April 8, 2021).
38. Gu B, De Gregorio M, Picipella JL, et al. Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. *BMJ Open*. 2021;11:e043921.
39. Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. *Curr Opin Rheumatol*. 2020;32:371–379.
40. Vande Casteele N, Abreu MT, Flier S, et al. Patients with low drug levels or antibodies to a prior anti-tumor necrosis factor are more likely to develop antibodies to a subsequent anti-tumor necrosis factor. *Clin Gastroenterol Hepatol*. 2022;20:465–467.
41. Chanchlani N, Lin S, Auth MK, et al. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the Immunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study. *Aliment Pharmacol Ther*. 2022;56:1250–1263.

42. Sparrow MP, Papamichael K, Ward MG, et al. Therapeutic drug monitoring of biologics during induction to prevent primary non-response. *J Crohns Colitis*. 2020;14:542–556.
43. Dubinsky MC, Mendiola ML, Phan BL, et al. Dashboard-driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity. *Inflamm Bowel Dis*. 2022;28:1375–1385.
44. Desai DC, Dherai AJ, Strik A, Mould DR. Personalized dosing of infliximab in patients with inflammatory bowel disease using a Bayesian approach: a next step in therapeutic drug monitoring. *J Clin Pharmacol*. 2023;63:480–489.
45. Papamichael K, Cheifetz AS. Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. *Expert Opin Drug Metab Toxicol*. 2021;17:1423–1431.
46. Lucidarme C, Petitcollin A, Brochard C, et al. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. *Aliment Pharmacol Ther*. 2019;49:147–154.
47. Petitcollin A, Brochard C, Siproudhis L, et al. Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases. *Clin Pharmacol Ther*. 2019;106:605–615.
48. Meredith J, Henderson P, Wilson DC, Russell RK. Combination immunotherapy use and withdrawal in pediatric inflammatory bowel disease—a review of the evidence. *Front Pediatr*. 2021;9:708310.
49. Drobné D, Bossuyt P, Breynaert C, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. *Clin Gastroenterol Hepatol*. 2015;13:514–521.
50. Drobné D, Kurent T, Golob S, et al. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. *Aliment Pharmacol Ther*. 2019;49:880–889.
51. Lega S, Phan BL, Rosenthal CJ, et al. Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD. *Inflamm Bowel Dis*. 2019;25:134–141.
52. Day AS, Gulati AS, Patel N, et al. The role of combination therapy in pediatric inflammatory bowel disease: a clinical report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr*. 2018;66:361–368.
53. Colombel JF, Adedokun OJ, Gasink C, et al. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis. *Clin Gastroenterol Hepatol*. 2019;17:1525–1532.e1.
54. Ungaro RC, Colombel J-F, Dubinsky MC, et al. Impact of thiopurine exposure on immunogenicity to infliximab is negligible in the setting of elevated infliximab concentrations. *Inflamm Bowel Dis*. 2022;28:649–651.
55. Spencer EA, Stachelski J, Dervieux T, Dubinsky MC. Failure to achieve target drug concentrations during induction and not HLA-DQA1*05 carriage is associated with antidrug antibody formation in patients with inflammatory bowel disease. *Gastroenterology*. 2022;162:1746–1748.e3.
56. Choi B, Sey M, Ponich T, et al. Decreased infliximab concentrations in patients with inflammatory bowel disease who carry a variable number tandem repeat polymorphism in the neonatal Fc receptor or variant HLA-DQA1*05G>A genotype. *Inflamm Bowel Dis*. 2023;29:437–443.
57. Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease. *Gastroenterology*. 2020;158:189–199.
58. Wilson A, Peel C, Wang Q, et al. HLA-DQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. *Aliment Pharmacol Ther*. 2020;51:356–363. Erratum in: *Aliment Pharmacol Ther*. 2021;54:1220.
59. Marquez-Megias S, Nalda-Molina R, Sanz-Valero J, et al. Cost-effectiveness of therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease: a systematic review. *Pharmaceutics*. 2022;14:1009.
60. Freeman K, Connock M, Auguste P, et al. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF- α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF- α -Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. *Health Technol Assess*. 2016;20:1–288.
61. Attar A, Duru G, Roblin X, et al. Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: a discrete event model study. *Dig Liver Dis*. 2019;51:112–119.
62. Negoescu DM, Enns EA, Swanhorst B, et al. Proactive vs reactive therapeutic drug monitoring of infliximab in Crohn's disease: a cost-effectiveness analysis in a simulated cohort. *Inflamm Bowel Dis*. 2020;26:103–111.
63. Yao J, Jiang X, You JHS. Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: a cost-effectiveness analysis. *J Gastroenterol Hepatol*. 2021;36:2397–2407.
64. Wu Y, Lin B, Thilakanathan C, et al. Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings. *Intern Med J*. 2021;51:739–745.
65. Ganesanathan S, Durai D. Clinical value and cost saving of therapeutic drug monitoring of infliximab in adult patients with inflammatory bowel disease. *Clin Med (Lond)*. 2020;20(suppl 2):s23–s24.
66. Taks M, Pijls PA, Derijks LJ, et al. Short article: the effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients. *Eur J Gastroenterol Hepatol*. 2017;29:169–173.
67. Bergqvist V, Holmgren J, Klintman D, Marsal J. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. *Aliment Pharmacol Ther*. 2022;55:1389–1401.
68. Little RD, Ward MG, Wright E, et al. Therapeutic drug monitoring of subcutaneous infliximab in inflammatory bowel disease—understanding pharmacokinetics and exposure response relationships in a new era of subcutaneous biologics. *J Clin Med*. 2022;11:6173.
69. Ritter E, Hirsch A, Isakov NF, et al. Higher maintenance adalimumab trough levels are associated with achievement of advanced remission targets in patients with inflammatory bowel disease. *J Clin Gastroenterol*. 2021;55:810–814.
70. Papamichael K, Clarke WT, Vande Castele N, et al. Comparison of assays for therapeutic monitoring of infliximab and adalimumab in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol*. 2021;19:839–841.e2.
71. Verdon C, Vande Castele N, Heron V, et al. Comparison of serum concentrations of ustekinumab obtained by three commercial assays in patients with Crohn's disease. *J Can Assoc Gastroenterol*. 2020;4:73–77.
72. Zulqarnain M, Deepak P, Yarur AJ. Therapeutic drug monitoring in perianal fistulizing Crohn's disease. *J Clin Med*. 2022;11:1813.
73. Rakowsky S, Cheifetz AS, Papamichael K. Editorial: is there a role for monitoring intermediate anti-TNF drug concentrations in IBD? *Aliment Pharmacol Ther*. 2022;55:1049–1050.
74. Hanžel J, Zdvoc J, Kurent T, et al. Peak concentrations of ustekinumab after intravenous induction therapy identify patients with Crohn's disease likely to achieve endoscopic and biochemical remission. *Clin Gastroenterol Hepatol*. 2021;19:111–118.e10.
75. Bossuyt P, Pouillon L, Claeys S, et al. Ultra-proactive therapeutic drug monitoring of infliximab based on point of care testing in inflammatory bowel disease: results of a pragmatic trial. *J Crohns Colitis*. 2022;16:199–206.
76. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. *Gastroenterology*. 2008;135:1114–1122.
77. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. *Gastroenterology*. 2008;135:1106–1113.
78. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. *Pharmacol Ther*. 2008;117:244–279.
79. Oude Munnink TH, Henstra MJ, Segerink LI, et al. Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant

- disease: translating TNF- α experience to oncology. *Clin Pharmacol Ther.* 2016;99:419–431.
80. Jongtsma MME, Winter DA, Huynh HQ, et al. Infliximab in young paediatric IBD patients: it is all about the dosing. *Eur J Pediatr.* 2020;179:1935–1944.
 81. Yao J, Jiang X, You JHS. A systematic review on cost-effectiveness analyses of therapeutic drug monitoring for patients with inflammatory bowel disease: from immunosuppressive to anti-TNF therapy. *Inflamm Bowel Dis.* 2021;27:275–282.
 82. Marquez-Megias S, Nalda-Molina R, Sanz-Valero J, et al. Cost-effectiveness of therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease: a systematic review. *Pharmaceutics.* 2022;14:1009.
 83. Singh N, Rosenthal CJ, Melmed GY, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis.* 2014;20:1708–1713.
 84. Naviglio S, Lacorte D, Lucafò M, et al. Causes of treatment failure in children with inflammatory bowel disease treated with infliximab: a pharmacokinetic study. *J Pediatr Gastroenterol Nutr.* 2019;68:37–44.
 85. Lucafò M, Curci D, Bramuzzo M, et al. Serum adalimumab levels after induction are associated with long-term remission in children with inflammatory bowel disease. *Front Pediatr.* 2021;9:646671.
 86. Franca R, Curci D, Lucafò M, et al. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. *Expert Opin Drug Metab Toxicol.* 2019;15:527–539.
 87. Curci D, Lucafò M, Cifù A, et al. Determination of serum infliximab concentration by point-of-care devices in children with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* 2019;69:474–479.
 88. Curci D, Lucafò M, Parisse P, et al. Atomic force microscopy application for the measurement of infliximab concentration in healthy donors and pediatric patients with inflammatory bowel disease. *J Pers Med.* 2022;12:948.
 89. Lucafò M, Franca R, Selvestrel D, et al. Pharmacogenetics of treatments for inflammatory bowel disease. *Expert Opin Drug Metab Toxicol.* 2018;14:1209–1223.
 90. Whirl-Carrillo M, Huddart R, Gong L, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther.* 2021;110:563–572.
 91. Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. *Curr Protoc Bioinformatics.* 2016;54:1–1.30.33.
 92. Curci D, Lucafò M, Cifù A, et al. Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease. *Clin Transl Sci.* 2021;14:2184–2192.
 93. Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. *BioDrugs.* 2018;32:425–440.
 94. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. *Ann Rheum Dis.* 2013;72:1613–1620.
 95. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. *Ann Rheum Dis.* 2013;72:1605–1612.
 96. Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. *Inflamm Bowel Dis.* 2017;23:233–243.
 97. Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. *Ann Rheum Dis.* 2017;76:1679–1687.
 98. Weinblatt ME, Baranaukaite A, Dokoupilova E, et al. Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. *Arthritis Rheumatol.* 2018;70:832–840.
 99. Barbier L, Ebbers HC, Declercq P, et al. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. *Clin Pharmacol Ther.* 2020;108:734–755.
 100. Fiorino G, Ruiz-Argüello MB, Maguregui A, et al. Full interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflammatory bowel disease. *Inflamm Bowel Dis.* 2018;24:601–606.
 101. Westhovens R, Wiland P, Zawadzki M, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. *Rheumatology (Oxford).* 2021;60:2277–2287.
 102. Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. *Gastroenterology.* 2021;160:2340–2353.
 103. Metcalfe C, Dougall T, Bird C, et al. The first World Health Organization International Standard for infliximab products: a step towards maintaining harmonized biological activity. *MAbs.* 2019;11:13–25.
 104. Wadhwa M, Bird C, Atkinson E, et al. The first WHO International standard for adalimumab: dual role in bioactivity and therapeutic drug monitoring. *Front Immunol.* 2021;12:636420.
 105. Stocco G, Martellosi S, Arrigo S, et al. Multicentric case-control study on azathioprine dose and pharmacokinetics in early-onset pediatric inflammatory bowel disease. *Inflamm Bowel Dis.* 2017;23:628–634.
 106. Bramuzzo M, Arrigo S, Romano C, et al. Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study. *United Eur Gastroenterol J.* 2019;7:759–766.
 107. ClinicalTrials.gov. Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study (EPIC). Available at: <https://clinicaltrials.gov/ct2/show/NCT05280405> (First Posted: March 15, 2022).